Exagen announces appointment of andrew l. concoff md, facr, caqsm, as chief innovation officer

San diego, oct. 04, 2022 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, today announced the appointment of andrew l. concoff m.d. facr, caqsm as chief innovation officer. in this role, dr. concoff will lead the company's rheumatoid arthritis medical initiatives, including the avise® radr platform (rheumatoid arthritis drug response). dr. concoff will be a key principal in strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures, as well as the advancement of innovative access partnerships with payors and governments globally.
XGN Ratings Summary
XGN Quant Ranking